What type of study is this?

This is a Human Clinical Trial study (also classified as: Phase 2, Pre-Registered Trial).

December 8, 2025Blood

Rituximab and epcoritamab as first-line therapy for patients with high-tumor burden follicular lymphoma: Results of a multicenter phase II trial

View Full Paper

Ask AI

Bookmark

Authors

Phase II trial shows Rituximab combined with Epcoritamab results in high response rates in follicular lymphoma, suggesting lower CRS risk.

Overall response rate reached 97% with 91% achieving complete metabolic response in patients.
15 patients (43%) experienced cytokine release syndrome, with those receiving three step-up doses showing significantly reduced rates.
Assessment using PET-CT based on Lugano 2014 criteria showed rapid responses after 2 treatment cycles.
These findings support continued exploration of this treatment regimen, highlighting the potential for reduced chemotherapy use.

Wallace et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

December 8, 2025Blood

View Full Paper

Ask AI

Bookmark

Authors

Phase II trial shows Rituximab combined with Epcoritamab results in high response rates in follicular lymphoma, suggesting lower CRS risk.

Overall response rate reached 97% with 91% achieving complete metabolic response in patients.
15 patients (43%) experienced cytokine release syndrome, with those receiving three step-up doses showing significantly reduced rates.
Assessment using PET-CT based on Lugano 2014 criteria showed rapid responses after 2 treatment cycles.
These findings support continued exploration of this treatment regimen, highlighting the potential for reduced chemotherapy use.

Wallace et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark